Fractyl Health (NASDAQ:GUTS) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Fractyl Health (NASDAQ:GUTS) from a strong sell rating to a hold rating in a report issued on Saturday morning.

Several other equities analysts have also recently weighed in on the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Fractyl Health in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Friday, April 24th. Finally, Morgan Stanley cut shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $8.00 to $2.00 in a research note on Thursday, January 29th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Price Performance

Shares of NASDAQ:GUTS opened at $0.86 on Friday. The firm’s 50 day moving average price is $0.56 and its 200-day moving average price is $1.13. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03. The company has a quick ratio of 4.78, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $136.53 million, a PE ratio of -0.67 and a beta of 2.11.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.23. Equities research analysts expect that Fractyl Health will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new stake in Fractyl Health during the 3rd quarter worth approximately $19,298,000. 683 Capital Management LLC raised its stake in Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after acquiring an additional 1,397,620 shares during the period. Marshall Wace LLP raised its stake in Fractyl Health by 234.9% during the 4th quarter. Marshall Wace LLP now owns 5,926,745 shares of the company’s stock worth $13,039,000 after acquiring an additional 4,156,969 shares during the period. Pale Fire Capital SE raised its stake in Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after acquiring an additional 2,711,103 shares during the period. Finally, Alyeska Investment Group L.P. bought a new stake in Fractyl Health during the 3rd quarter worth approximately $8,981,000.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.